ASRT CEO Mark Reisenauer Sells Shares on June 16
CEO Mark Reisenauer sold 98,748 shares of ASRT, joining other insiders in recent sales.
Key Points
- On June 16, 2026, ASRT CEO Mark Reisenauer sold 98,748 shares, marking a significant insider transaction.
- ASRT shares traded at $23.5, with recent analyst targets ranging from $18 to $23.5.
- Other insiders, including EVP and CFO Ajay Patel, also sold shares on the same day.
On June 16, 2026, Mark Reisenauer, the CEO of ASRT, sold 98,748 shares of the company. This move is part of a broader pattern of insider selling at ASRT, with multiple executives unloading shares on the same day.
Insider Buying and Selling at ASRT
Mark Reisenauer, ASRT's CEO, wasn't the only executive selling shares on June 16. Ajay Patel, the Executive Vice President and CFO, sold 72,051 shares. Other insiders including Kirk Sigurd, David Matthew Stark, and Paul Schwichtenberg, the President and COO, also sold shares. These transactions were not part of any planned trading program.
Other Institutional Activity in ASRT
Nantahala Capital Management, LLC increased its holdings in ASRT by 105,000 shares, ending with 692,335 shares valued at approximately $13.2 million. Vanguard Capital Management LLC acquired 268,952 shares, bringing its total to the same amount, valued at about $5.1 million. Meanwhile, Opaleye Management Inc. reduced its position by 19,293 shares, holding 265,707 shares worth around $5.1 million. Renaissance Technologies LLC added 37,902 shares to hold 228,599 shares valued at $4.4 million.
Analysts Set New Price Targets
On May 13, 2026, Lake Street maintained a hold rating on ASRT, setting a price target of $23.5. Earlier, on May 5, HC Wainwright & Co. also maintained a hold rating with a target of $21.8. In April, both firms downgraded the stock to a hold, with a target of $18.
About ASRT
ASRT operates in the pharmaceutical sector, focusing on developing and marketing medications for various health conditions. The company, headquartered in the United States, aims to provide innovative solutions to enhance patient care and improve health outcomes.
Bottom Line
The recent insider sales, including that of CEO Mark Reisenauer, highlight significant selling activity within ASRT. Investors often monitor such moves to gauge executive sentiment. It's important to remember that these transactions are disclosed after they occur and may not reflect current insider positions. Analyst ratings suggest a mixed outlook, with targets ranging from $18 to $23.5.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.